Your Blood Pressure's Backup Plan

Here's a number that should make your blood boil: $745. That's what a single bottle of Qbrelis—the only FDA-approved liquid form of Lisinopril—costs right now in early 2026. The same medication in tablet form? Four dollars a month. Generic. Everywhere. No drama.

The liquid version isn't a luxury. It's a necessity for children with congenital hypertension and elderly patients who can't swallow pills. And right now, a severe supply shortage has made it nearly impossible to find. Clinicians are being forced into workarounds: compounded suspensions from specialty pharmacies (inconsistent quality, insurance won't cover them), or pivoting patients to Enalapril solution—a different drug entirely.

This is the pharmaceutical access paradox in miniature. The active ingredient is dirt cheap—among the most affordable generics on Earth. But the moment you need it in a different delivery form, you're at the mercy of a single manufacturer and a supply chain that apparently can't handle one factory hiccup without leaving the most vulnerable patients scrambling.

Postpartum hypertension is one of those clinical nightmares that doesn't get the attention it deserves. A woman survives pregnancy, delivers her baby, and then her blood pressure spikes dangerously in the days after. The standard treatment has been Nifedipine ER—a calcium channel blocker. It works. But a major new trial says Lisinopril works better.

The ACE Trial (NCT05049616), analyzed in a systematic review published in AJOG, compared Lisinopril combined with Hydrochlorothiazide against Nifedipine ER for controlling blood pressure in the first 7-10 days after childbirth. The results weren't subtle: only 27% of women on the Lisinopril combination needed readmission or further escalation, compared to 43% on Nifedipine. Bayesian analysis put the probability of Lisinopril/HCTZ superiority at 85%.

The implication is significant. Postpartum preeclampsia management hasn't had a major shakeup in years. If these results hold through larger confirmatory trials, Lisinopril/HCTZ could become the new standard of care for a condition that affects roughly 1 in 10 pregnancies complicated by hypertension. That's a lot of women whose hospital stays could be shorter and safer.

Some patients do everything right. They take their Lisinopril. They add a diuretic. They add a calcium channel blocker. Three drugs, maximum doses, and their blood pressure still won't budge. That's resistant hypertension, and it affects roughly 10-15% of people on treatment. For these patients, the Phase III results from the BaxHTN trial are genuinely exciting.

Baxdrostat works by a completely different mechanism than ACE inhibitors. Where Lisinopril blocks the conversion of angiotensin I to angiotensin II, Baxdrostat inhibits aldosterone synthase—cutting off excess aldosterone production at its source. In the trial, published in the NEJM, patients with resistant hypertension saw an additional 20 mmHg drop in systolic blood pressure when Baxdrostat was added to their existing triple therapy.

To put that 20 mmHg in context: that's the difference between Stage 2 hypertension (where your stroke risk is dramatically elevated) and a controlled reading. For patients who've been told "we've tried everything," this is the first compelling new option in years. Baxdrostat doesn't replace Lisinopril—it picks up where Lisinopril leaves off.